Legeay S - Search Results

1

[An online tool to personalize the drug-doses for obese adults].

Gouju J, Jourdan C, Legeay S. Gouju J, et al. Among authors: legeay s. Therapie. 2024 May-Jun;79(3):379-392. doi: 10.1016/j.therap.2023.07.004. Epub 2023 Jul 28. Therapie. 2024. PMID: 37865563 Review. French.

2

Epigallocatechin Gallate: A Review of Its Beneficial Properties to Prevent Metabolic Syndrome.

Legeay S, Rodier M, Fillon L, Faure S, Clere N. Legeay S, et al. Nutrients. 2015 Jul 7;7(7):5443-68. doi: 10.3390/nu7075230. Nutrients. 2015. PMID: 26198245 Free PMC article. Review.

3

Two dechlorinated chlordecone derivatives formed by in situ chemical reduction are devoid of genotoxicity and mutagenicity and have lower proangiogenic properties compared to the parent compound.

Legeay S, Billat PA, Clere N, Nesslany F, Bristeau S, Faure S, Mouvet C. Legeay S, et al. Environ Sci Pollut Res Int. 2018 May;25(15):14313-14323. doi: 10.1007/s11356-017-8592-6. Epub 2017 Feb 16. Environ Sci Pollut Res Int. 2018. PMID: 28210952 Free article.

4

The insect repellent N,N-diethyl-m-toluamide (DEET) induces angiogenesis via allosteric modulation of the M3 muscarinic receptor in endothelial cells.

Legeay S, Clere N, Hilairet G, Do QT, Bernard P, Quignard JF, Apaire-Marchais V, Lapied B, Faure S. Legeay S, et al. Sci Rep. 2016 Jun 27;6:28546. doi: 10.1038/srep28546. Sci Rep. 2016. PMID: 27345502 Free PMC article.

5

Pharmacokinetics of obese adults: Not only an increase in weight.

Gouju J, Legeay S. Gouju J, et al. Among authors: legeay s. Biomed Pharmacother. 2023 Oct;166:115281. doi: 10.1016/j.biopha.2023.115281. Epub 2023 Aug 11. Biomed Pharmacother. 2023. PMID: 37573660 Free article. Review.

6

A revisited version of the disputatio for pharmacological training: An educational study.

Carton L, Bordy R, Totoson P, Laforgue EJ, Pelerin JM, Portier-Feunteun T, Mainbourg S, Deplanque D, Zimmer L, Laporte S, Bordet R, Grenet G, Legeay S. Carton L, et al. Among authors: legeay s. Therapie. 2023 Nov 18:S0040-5957(23)00184-1. doi: 10.1016/j.therap.2023.10.016. Online ahead of print. Therapie. 2023. PMID: 38008601

7

FRET as the tool for in vivo nanomedicine tracking.

Kaeokhamloed N, Legeay S, Roger E. Kaeokhamloed N, et al. Among authors: legeay s. J Control Release. 2022 Sep;349:156-173. doi: 10.1016/j.jconrel.2022.06.048. Epub 2022 Jul 7. J Control Release. 2022. PMID: 35779657 Free article. Review.

8

Specificity of pharmacokinetic modeling of nanomedicines.

Lebreton V, Legeay S, Saulnier P, Lagarce F. Lebreton V, et al. Among authors: legeay s. Drug Discov Today. 2021 Oct;26(10):2259-2268. doi: 10.1016/j.drudis.2021.04.017. Epub 2021 Apr 20. Drug Discov Today. 2021. PMID: 33892140 Review.

9

The dichotomous activities of microglia: A potential driver for phenotypic heterogeneity in Alzheimer's disease.

Pumo A, Legeay S. Pumo A, et al. Among authors: legeay s. Brain Res. 2024 Jun 1;1832:148817. doi: 10.1016/j.brainres.2024.148817. Epub 2024 Feb 22. Brain Res. 2024. PMID: 38395249 Free article. Review.

10

Is bisphenol A an environmental obesogen?

Legeay S, Faure S. Legeay S, et al. Fundam Clin Pharmacol. 2017 Dec;31(6):594-609. doi: 10.1111/fcp.12300. Epub 2017 Jul 7. Fundam Clin Pharmacol. 2017. PMID: 28622415 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

35 results

Search Page